These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 27354104)

  • 1. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer.
    Li N; Dou L; Zhang Y; Jin J; Wang G; Xiao Q; Li Y; Wang X; Ren H; Fang H; Wang W; Wang S; Liu Y; Song Y
    Gastrointest Endosc; 2017 Mar; 85(3):669-674. PubMed ID: 27354104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
    Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
    Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 5. Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
    Larsen FO; Markussen A; Jensen BV; Fromm AL; Vistisen KK; Parner VK; Linnemann D; Hansen RH; Johannesen HH; Schou JV
    Clin Colorectal Cancer; 2017 Jun; 16(2):e7-e14. PubMed ID: 27743742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
    Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
    Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Chennupati SK; Quon A; Kamaya A; Pai RK; La T; Krakow TE; Graves E; Koong AC; Chang DT
    Am J Clin Oncol; 2012 Aug; 35(4):334-9. PubMed ID: 21422989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
    Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
    Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer].
    Xiao L; Huang R; You K; Chang H; Qiu B; Xiao W; Chen L; Gao Y; Liu M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Mar; 17(3):219-24. PubMed ID: 24671807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
    Yang Y; Liu Q; Jia B; Du X; Dai G; Liu H; Chen J; Zeng M; Wen K; Zhu Y; Wang Y; Feng L
    Technol Cancer Res Treat; 2019 Jan; 18():1533033818824367. PubMed ID: 30803368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
    Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
    Zeng ZF; Ding PR; Pan ZZ; Lin JZ; Li LR; Lu ZH; Wu XJ; Kong LH; Zhou ZG; Wan DS
    Ai Zheng; 2009 Sep; 28(9):923-7. PubMed ID: 19728908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
    Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can Endorectal Ultrasound, MRI, and Mucosa Integrity Accurately Predict the Complete Response for Mid-Low Rectal Cancer After Preoperative Chemoradiation? A Prospective Observational Study from a Single Medical Center.
    Liu S; Zhong GX; Zhou WX; Xue HD; Pan WD; Xu L; Lu JY; Wu B; Lin GL; Qiu HZ; Xiao Y
    Dis Colon Rectum; 2018 Aug; 61(8):903-910. PubMed ID: 29944579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
    Lombardi R; Cuicchi D; Pinto C; Di Fabio F; Iacopino B; Neri S; Tardio ML; Ceccarelli C; Lecce F; Ugolini G; Pini S; Di Tullio P; Taffurelli M; Minni F; Martoni A; Cola B
    Ann Surg Oncol; 2010 Mar; 17(3):838-45. PubMed ID: 20012700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
    Wang CC; Liang JT; Tsai CL; Chen YH; Lin YL; Shun CT; Cheng JC
    World J Surg Oncol; 2014 Nov; 12():329. PubMed ID: 25373828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.